Gamma cameras to remain stable and PET to decline in European nuclear
medical imaging markets
15 May 2006 London, UK. Market analysts Frost & Sullivan have reported
that the increasingly mature European nuclear medical imaging markets will
be revitalised by the introduction of new technologies. Despite relative
stability, innovative and enhanced imaging techniques such as SPECT will
energise the saturated gamma camera segment. Moreover, PET-CT scanners will
rapidly replace existing PET systems, resulting in revenue attenuation.
The European Nuclear Medicine Imaging Systems Markets earned revenues of
US$155.7 million in 2005 and is estimated to reach US$138.9 million in 2010.
"Increased attention towards molecular imaging will be one of the key
drivers for the nuclear medicine market," notes Frost & Sullivan Industry
Analyst, Srividya Badrinarayanan. "As R&D focus shifts towards molecular
imaging, the advancements in and the presence of imaging modalities for
nuclear imaging would be very essential for its growth." Molecular imaging
is now considered the technology of the future as it provides detailed
information about diseases and methods to treat them. This will promote the
uptake of advanced technologies in nuclear medicine imaging. Saturation in
the gamma market can be overcome only through the introduction of new
applications. In the case of the PET scanners market, the availability of
its radioisotopes will generate additional interest among end users.
"Constant technological innovation is one of the key factors for the growth
of this market," says Ms. Badrinarayanan. "Companies need to continually
develop and introduce new technologies as well as expand clinical
applications for the present one - all of which requires increased R&D
efforts and a focus on evolving customer preferences." To sustain their
profitability, market vendors need to design appropriate pricing plans for
their systems and create more awareness on the advantages of new
technologies and applications. Also, an adequate focus on partnering with
radiopharmaceuticals companies will help market participants offer
comprehensive solutions to customers.
For more information on the study see
www.frost.com To top
|